RT Book, Section
A1 Spragg, David
A1 Calkins, Hugh
A2 Fuster, Valentin
A2 Narula, Jagat
A2 Vaishnava, Prashant
A2 Leon, Martin B.
A2 Callans, David J.
A2 Rumsfeld, John S.
A2 Poppas, Athena
SR Print(0)
ID 1202446998
T1 Supraventricular Tachycardia: Atrial Tachycardia, Atrioventricular Nodal Reentry, and Wolff-Parkinson-White Syndrome
T2 Fuster and Hurst's The Heart, 15e
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264257560
LK accessmedicine.mhmedical.com/content.aspx?aid=1202446998
RD 2024/04/18
AB Chapter  SummaryThis  chapter  discusses  the  mechanisms  and  treatment  of  supraventricular  tachycardia  (SVT),  a  term  that  encompasses  three  distinct  arrhythmias:  atrioventricular  nodal  reentrant  tachycardia  (AVNRT),  atrioventricular  reciprocating  tachycardia  (AVRT),  and  atrial  tachycardia  (AT).  These  arrhythmias,  while  not  life  threatening,  can  cause  significant  symptoms  in  afflicted  patients  including  palpitations,  dizziness,  and  syncope.  AVNRT  accounts  for  roughly  two-thirds  and  AVRT  for  nearly  one-third  of  SVT  cases.  AVNRT  and  AVRT  are  reentrant  rhythms,  while  AT  can  be  due  to  triggering  or  automaticity  (see  Fuster  and  Hurst’s  Central  Illustration).  The  reentrant  circuit  for  AVNRT  includes  pathways  with  distinct  electrophysiological  properties  within  the  atrioventricular  node,  while  the  circuit  for  AVRT  includes  the  atrioventricular  node  and  an  extranodal  accessory  pathway.  Frequently,  SVTs  can  be  terminated  acutely  with  vagal  maneuvers.  Long-term  management  options  include  chronic  suppression  with  antiarrhythmic  medications  or  definitive  therapy  with  catheter  ablation.